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Abstract
Background: Multiple endocrine neoplasias type 2A (MEN 2A) is a dominantly inherited cancer
syndrome. Missence mutations in the codon encoding cysteine 634 of the ret proto-oncogene have
been found in 85% of the MEN 2A families. The main tumour type always present in MEN 2A is
medullar thyroid carcinoma (MTC). Only 25% of all MTC are hereditary, and generally they are
identified by a careful family history. However, some familial MTCs are not easily detected by this
means and underdiagnosis of MEN 2A is suspected.
Methods: DNA samples from MEN 2A patients were amplified by PCR. The products were
incubated with the restriction enzyme Bst ApI or Bgl I.
The samples were loaded in non-denaturing 10% Polyacrilamyde Gel and run at 120 volts for 40
min. The gels were stained with 10 µg/ml ethidium bromide, and the bands were visualized under
a UV lamp.
Results: We developed a PCR-mutagenic method to check the integrity of the three bases of the
cysteine 634 codon.
Conclusion: The method can be used to detect inherited mutations in MTC patients without a
clear family history. The method is relatively simple to use as a routine test in these patients to
decrease the underdiagnosis of MEN 2A. In addition, the assay can be used to screen affected
families with any mutation in cysteine 634.
Background
Multiple endocrine neoplasia type 2A (MEN 2A) is a dom-
inantly inherited cancer syndrome, which involves the tri-
ad of medullary thyroid cancer (MTC),
pheochromocytoma, and hyperparathyroidism. It is in-
herited as an autosomal dominant trait. Missense muta-
tions in the codon encoding cysteine 634 of the ret proto-
oncogene have been found in 85% of the reported fami-
lies [1]. Other mutations in the same cysteine-rich do-
main of the protein can also cause MEN 2A. All these
mutations lead to the replacement of a cysteine by an al-
ternate amino acid.
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The ret gene is expressed in neural crest derived tissues [2].
It encodes a receptor with tyrosine kinase activity that is
essential for the normal development of the kidneys and
the intestinal nervous system [3]. This protein is consid-
ered a dependence receptor because it provokes prolifera-
tion in the presence of its ligand, and cell death in its
absence [4,5]. The mutations associated with MEN 2A
cause ligand-independent constitutive activation of the ty-
rosine kinase receptor by the formation of disulfide-bond-
ed homodimers [6–9]. The main tumour type always
present in MEN-2A is MTC, accompanied in 50% of the
cases by pheocromocytoma and in 15–30% by parathy-
roid hyperplasia. MTC arises from the proliferation of
parafollicular or C cells of the thyroid. About 25% of all
MTCs are hereditary, the remainder are sporadic. At
present, hereditary MTC is identified mainly by a careful
analysis of the family history. However, about 15–20% of
the patients with familial MTC do not have a clear hered-
itary history, a pheochromocytoma or any other condi-
tion that would clearly indicate the familial background
of the disease (personal communication, Oliver Gimm).
This means that about 5% off all patients with MTC have
hereditary MTC that cannot be identified by the analysis
of the family history. Higher underdiagnosis of hereditary
cases would be expected in developing countries due to
poor family information and lack of routine mutation
analysis in MTC patients. Since the ret proto-oncogene has
a "hot-spot" site at the codon 634 in exon 11, the aim of
our group has been to develop a PCR-directed mutagene-
sis strategy to test the integrity of this codon. The assay is
relatively simple and can be applied as a routine analysis
for MTC patients and to screen MEN 2A affected families.
Materials and methods
DNA samples of MEN 2A patients that had been previous-
ly diagnosed as carriers of a hereditary mutation were used
[10]. DNA was extracted from 3 ml of entire blood using
the saline extraction procedure [11]. The PCR primers
used were, 5'ATCCACTGTGCGGCAAGCTG (forward)
and 5'AAGAGGACAGCGGCTGCGATGCCCGTGCG (re-
verse). The PCR programme consisted of 30 cycles of 94°C
30 sec, 55°C 2 min and 72°C 30 sec, with an initial and
final hold of 94°C 3 min, and 72°C 3 min, respectively.
PCR products were incubated with 0.5 µl of Bst ApI (10 U/
µl New England Biolabs, Buenos Aires, Argentina) or Bgl I
(10 U/µl Promega, Buenos Aires, Argentina), in a 25 µl re-
action volume. The same reaction replacing the enzyme
with miliQwater was used as negative control. Incubation
with the Bgl I enzyme was performed for 2 h at 37°C; in-
cubation with the BstApI enzyme was performed for 4 h
at 60°C, and 1 µl of enzyme was added to each tube for a
second 4 h incubation at 60°C.
The samples were loaded in non-denaturing 10% Poly-
acrilamyde Gel and ran at 120 volt for 40 min. The gels
were stained with 10 µg/ml ethidium bromide, and the
bands were visualized under a UV lamp.
Results
Our goal was to design a strategy in which the PCR prod-
uct would contain the 634 codon and one (or more) re-
striction sites present only in the wild type allele. The
codon 634 (TGC) and its neighbouring nucleotides do
not form a palindromic site for any restriction enzyme.
Two restriction sites were created introducing point muta-
tions with the PCR primers. The restriction site introduced
with the forward primer is cut by BstApI and is disturbed
by mutations in any of the three bases of the codon. The
second restriction site is generated with the reverse primer
and is recognized by BglI. Any mutation in the last two
bases of the codon alters this restriction site (Fig 1).
Four different DNA samples were amplified, a wild type
sample, and three DNAs each with one of the three bases
of the 634 codon mutated (TGC to CGC, TAC or TGG).
Preliminary assays showed that only partial cut of the wild
type allele was observed after incubation with the BstApI
enzyme for 4 h at 60°C. A second incubation adding fresh
enzyme rendered a total cut of the wild type allele (Fig. 2).
In general, DNA samples from MEN 2A patients are heter-
ozygous carrying a wild type allele and a mutated allele.
Fig. 2 shows that, in these samples, BstApI can cut only a
small proportion of the PCR product. Most of the product
is not cut because the enzyme fails to recognize not only
the mutated strains but also the heteroduplex formed be-
tween the mutated and the wild type strains that hybridiz-
es during the PCR amplification.
The same PCR-products incubated with the Bgl I enzyme
were completely digested only in the case of the wild type
DNA or when the mutation was present in the first base
(Fig. 3).
The results show that the complete 634 codon can be
checked by a PCR amplification and an incubation with
BstApI. The incubation with the BglI enzyme permits a
double-check for mutations in the last two bases. Products
that are not recognized by BstApI but are cut by BglI are
likely mutated in the first base of the 634 codon.
Discussion
Several mutations in the 634 codon related to MEN 2A
create recognition sites for restriction endonucleases.
Therefore, the analysis of restriction fragments has been
extensively used to screen MEN 2A-affected families.
However, in these studies, the mutations present in the
families were first identified by sequencing the exon 11 in
an affected member of the family. In a second step, if theBMC Medical Genetics 2002, 3 http://www.biomedcentral.com/1471-2350/3/4
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mutation introduced a restriction site, a PCR based restric-
tion analysis was designed to screen the rest of the family.
The method that is described in this report checks (or dou-
ble-checks) the integrity of the three bases of the 634 co-
don. Therefore, it can be used to detect mutations in MTC
patients without a clear family history and to screen affect-
ed families with any mutation in the 634 hot-spot. If a
mutation is detected, the necessary following step is to se-
quence the region and confirm which base is altered. This
will avoid to mis-diagnose the polymorphism TGC>TGT,
that would be detected by our strategy as a mutation, but
that still codifies for a cystein,.
Figure 1
Design of the mutagenic primers, and the restriction sites of the BstApI and BglI enzymes.
Figure 2
Check of the integrity of codon 634 with the BstApI
enzyme. DNA samples were amplified using the forward
and reverse primers shown in figure 1. The PCR product was
incubated in the presence (lane 1–4) or absence (lane 5) of
BstApI. The restriction fragments were run in a non-denatur-
ing 10% PAGE. Lane 1: mutation in the first base of the 634
codon (T>C); lane 2: mutation in the second base of the 634
codon (G>A); lane 3: mutation in the third base of the 634
codon (C>G); lane 4: wild type 634 codon; lane 5: wild type
634 codon without enzyme incubation. Both alleles are com-
pletely cut by the enzyme in the wildtype codon, which
means that the codon is correct. In the rest of the samples,
the product is not completely cut, which reveals that one
allele is mutated at one of the three bases of codon 634.
Figure 3
Check of the integrity of codon 634 with the Bgl I
enzyme. DNA samples were amplified using forward and
reverse primers shown in figure 1. The PCR product was
incubated in the presence (lane 2–5) or absence (lane 1) of
Bgl I. The restriction fragments were run in a non-denaturing
10% PAGE. Lane 1: wild type 634 codon without enzyme
incubation ; lane 2: wild type 634 codon ; lane 3: mutation in
the first base of the 634 codon (T>C); lane 4: mutation in the
second base of the 634 codon (G>A); lane 5: mutation in the
third base of the 634 codon (C>G). Both alleles are com-
pletely cut by the enzyme in lane 2 and 3, which means that
at least the second and third bases of the codon are correct.
In lane 4 and 5, the product is not completely cut, which
reveals that one allele has a mutation at the second or third
base of codon 634.BMC Medical Genetics 2002, 3 http://www.biomedcentral.com/1471-2350/3/4
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Conclusions
The method is relatively simple to be used as a routine de-
tection method for ret proto-oncogene mutations in
cystein 634 in the blood of MTC patients. The test would
help decrease the underdiagnosis of the familial MTC that
in developed countries accounts for about 5% and that is
probably higher in developing countries. The method can
also be applied to screen MEN 2A families and to detect
somatic mutations in cysteine 634 of the ret-protoonco-
gen in other tumors to better understand the role of this
receptor in malignant proliferation [12].
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